

Vaccibody appoints Harald Gurvin as new Chief Financial Officer

Oslo, Norway, April 28, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today the appointment of Harald Gurvin as the Company’s Chief Financial Officer (CFO).

Harald Gurvin (47) has as a strong track-record and financial background with many years of experience in large international companies.

Harald Gurvin comes to Vaccibody from a position as CFO in Flex LNG, a company owning and operating LNG (liquefied natural gas) carriers and listed on both the New York Stock Exchange and the Oslo Stock Exchange. Prior to Flex LNG, he was CFO in SFL Corporation Limited (the former Ship Finance International Limited), a leading international ship and rig owning company listed on the New York Stock Exchange. Harald Gurvin holds a M.Sc. degree in Shipping, Trade and Finance from CASS Business School, and a M.Sc. degree in Marine Engineering and Naval Architecture from the Norwegian University of Sciences and Technology (NTNU).

Chief Executive Officer of Vaccibody, Michael Engsig, states: “I am excited to announce that Harald Gurvin will join our leadership team as Chief Financial Officer. We have conducted an extensive international search for a leader to bring onboard a very comprehensive international financial skillset. In his previous role, he was responsible for the listing process on the New York Stock Exchange. This is a unique experience that is very relevant in connection with Vaccibody’s capital market strategy which includes exploration of a potential listing on Nasdaq Global Market in the United States.”

Harald Gurvin will commence his new role at Vaccibody on May 3, 2021.

About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead

product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. Further, the Company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COVID.

Vaccibody's shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at <http://www.vaccibody.com>

Contact for Vaccibody:

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
mengsig@vaccibody.com

Vaccibody AS

Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway

Forward-looking statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.